Sanofi commits $1.7B to buy Inhibrx, but wants just a single drug

The latest stories trending on MedCity News.

Editor's Pick

Top Story Sanofi Commits $1.7B to Buy an Entire Company, But Wants Just a Single Drug Sanofi is acquiring Inhibrx to get its hands on a drug candidate in pivotal testing for the protein deficiency alpha-1 antitrypsin deficiency, which leads to lung and liver problems. Inhibrx's remaining assets will be spun out into a new company. Sponsored Content Seeking a Total Patient View? Look No Further. Presented by Medidata Solutions Gain a truly integrated experience that easily & accurately captures data from patients, caregivers and clinicians in traditional, hybrid or fully decentralized trials for a 360° patient view.  Learn More. Check Out This Pre-Conference Workshop at INVEST 2024 Did you know the U.S. Government funds startups and is a great source for small business support? Chris Sasiela, Director, Innovator SEED Innovator Support Services, from NIH will cover resources and programs available to enhance a portfolio startup's success. Including access to entrepreneurs-in-residence, subject matter experts in regulatory and reimbursement, gap analyses, entrepreneurial training and more. Secure your spot today and save. Register Now for $995 [rate ends Feb 16th]

Featured News

Technology as a Cure: Alleviating Clinician Burnout, Empowering Pharmacists to Fill Care Gaps This Cold and Flu Season In 61% of counties with a PCP shortage, there is a high volume of retail pharmacies. It reveals an opportunity for pharmacists, who have the education and training, and are already providing vaccinations, tests and frontline treatments to amplify the impact they can have on providing accessible care in the communities they serve. What's Next for Clinical Decision Support Tools? Technology evolved over these five decades to respond to the needs of users. Based on my experience and interactions with other leaders in the market, here are three technology trends I expect in 2024. FDA Calls for New Safety Warning for the Class of CAR T Cancer Therapies Two months after announcing an inquiry into reports of new cancers in patients treated with CAR T-cell therapies, the FDA is directing makers of these therapies to add new safety warnings to product labels describing this risk. Companies have 30 calendar days to comply. Lightfully Behavioral Health Launches Virtual Offering for College Students Lightfully Behavioral Health unveiled Lightfully U last week. The virtual intensive outpatient program is specifically designed for college students and offers primary and family therapy, access to a psychiatrist, group sessions and other support. Turquoise Health Raises $30M for its Price Transparency Software Turquoise Health closed a $30 million Series B round, which brings its total funding to date to $55 million. The San Diego-based startup, which has more than 160 customers, sells a platform that makes it easier for hospitals and payers to comply with price transparency regulations. The Weight Loss Market in 2024: 3 Key Questions We Can No Longer Ignore In 2024, the weight loss market finds itself at a crossroads, grappling with pivotal questions that will shape the future. The winners will prioritize affordable lifelong care, scalable coaching and support, and a diverse set of solutions that give people second and third chances along their weight loss journeys.

Resources

MedCity FemFwd: Shortcomings in Menopause Care with Dr. Bruce Dorr In this episode, we were joined by Dr. Bruce Dorr, an OB-GYN and senior medical advisor for Biote, a hormone optimization company. Just about every woman will go through menopause, yet treatment is inadequate. This comes down to the lack of medical training for menopause care, according to Dorr. He discusses why this is and what needs to change. Listen Now

MedCity News • PO Box 901 • New York, NY unsubscribe